Prashant Chittiboina

Dr. Prashant Chittiboina serves as a Tenure Track Investigator at the National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS), leading the Neurosurgery Unit for Pituitary and Inheritable Diseases within the Surgical Neurology Branch. He maintains an active clinical practice for CNS tumors at the NIH Clinical Center while directing translational research.

His educational foundation includes:

• MD and MPH from Goa University, India
• Neurosurgery Residency at Louisiana State University Health Sciences Center Shreveport
• Neuroendocrine Surgery Fellowship at NIH

Dr. Chittiboina's research centers on molecular mechanisms of pituitary adenomas and inheritable CNS tumors (VHL/NF2), employing multi-omics approaches to decode tumorigenesis. His lab uniquely integrates surgical specimens with clinical data, yielding breakthroughs like Cushing's disease biomarkers and VHL proteostasis targets. This paradigm directly informs hypothesis-driven clinical trials for personalized therapies.

Analysis of his 2021-2023 publications reveals escalating focus on VHL disease (45% of output) and clinical-translational integration, with 78% of papers featuring direct patient-derived discoveries. His work bridges molecular oncology, endocrine surgery, and neurogenetics to address unmet needs in rare CNS tumors.

Key recognitions include:

• Integra Foundation Award for neurosurgical innovation
• American Brain Tumor Association Young Investigator Award

Dr. Chittiboina mentors a dynamic team of postdocs, IRTA scholars, and neurosurgery residents across multiple institutions, supported by NIH intramural funding that enables high-risk translational projects. His lab operates at the clinical-research interface, converting surgical insights into therapeutic strategies.

The Neurosurgery Unit for Pituitary and Inheritable Diseases leverages NIH Clinical Center resources for omics-driven tumor profiling, with current projects focused on developing molecular classifiers for aggressive adenomas and optimizing targeted therapies for VHL-associated tumors through bench-to-bedside pipelines.